Live
FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 testEndpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 studyBioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haulEndpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugsEndpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotechFierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameSchunkHealthy and thriving: ARPM, MAPP companies maintain safety as top priority - Rubber News10x Genomics Blog10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocusClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreetClinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary era

Archive

Latest Oldest
Total 13530
Page 730 / 752
Query --